Navigation Links
Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes
Date:12/7/2008

s were matched for four out of six alleles for each patient. For the cultured cord blood cells, two patients received a five-out-of-six allele match and four patients received a four-out-of-six allele match. There was an average CD34+ increase of 160 (range 41 to 382), meaning that for every one CD34+ cell, there were 160 CD34+ cells after the culture, with an average total nucleated cell fold increase of 660 (range 146 to 1496). A control group of 17 patients underwent an identical transplant regimen, but received two non-cultured cord blood units.

A relatively rapid engraftment time, averaging 14 days, was observed in the six patients in the experimental group compared with 25 days for the patients in the control group. The contribution of the expanded and non-cultured cord blood cells was determined by a DNA-based assay beginning seven days following the transplant. In the five patients with early engraftment, the engrafted cells present at day seven were derived almost entirely from the cultured unit. Persistent contribution to engraftment from the cultured cells was noted in two patients. One patient had persistent contribution from the cultured cells through 280 days post-transplant that was no longer noticeable at one year, and the second patient continued to demonstrate contribution from the cultured cells at 180 days post-transplant. One patient died on day 462 from a rare complication of myelitis (inflammation of the spinal cord) caused by the varicella-zoster virus, while all other patients were still in remission.

Non-Myeloablative Hematopoietic Stem Cell Transplantation in Older Patients With AML and MDS: Results From the Center for International Blood and Marrow Transplant Research (CIBMTR) [Abstract #346]

Sergio Giralt, MD, The University of TexasM. D. Anderson Cancer Center, Houston, TX

This stud
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ZIONA, Israel , June 29, ... BVXV, TASE: BVXV) today announced positive preliminary results from ... candidate for a universal influenza vaccine. In this trial, ... of 50 to 65, followed by an administration of ... later. M-001 was found to be safe and well ...
(Date:6/29/2015)... Calif. , June 29, 2015  Isis Pharmaceuticals, ... has been added to the Russell 1000 Index, effective ... performance of the large-cap segment of the U.S. equity ... Index and includes approximately 1000 of the largest securities ... current index membership. "We are pleased to ...
(Date:6/29/2015)... Calif. , June 29, 2015  Arbor ... medical workstation lineup. The high-powered, multi-functional M2150 ... generation Intel® Haswell Core i5-4402E 1.6 ... provide significant data processing and computing performance. Integrated ... making the unit well suited for graphics-intense applications ...
Breaking Medicine Technology:BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... , CHEYENNE, Wyo., Aug. 24 The ... of its Pay-for-Participation (P4P) program, a component of its innovative ... collaboration between the practitioner community and the Wyoming EqualityCare (EC) ... Wyoming Medicaid members. , , (Logo: ...
... Curemark Founder and CEO Dr. Joan Fallon delivered the ... Conference at Harvard Medical School on July 14th. , ... conclave is particularly significant, since epigenetics is the study of ... in the DNA sequence. Presenters at the session showcased many ...
Cached Medicine Technology:Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 2Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 3Curemark CEO Presents at Epigenomics Conference 2
(Date:6/29/2015)... ... June 29, 2015 , ... ... series as part of its support program. This discussion series is part of ... other support services to those affected by mesothelioma. , The six week discussion ...
(Date:6/29/2015)... ... 2015 , ... The Society for Immunotherapy of Cancer (SITC) ... accelerated approval of Bristol-Myers Squibb’s Opdivo® (nivolumab) for the treatment of metastatic melanoma. ... nivolumab for patients with metastatic melanoma in Europe represents a major advance in ...
(Date:6/29/2015)... , ... June 29, 2015 , ... ... now being offered at NewYork-Presbyterian/Weill Cornell Medical Center. The device is the first ... an alternative to continuous positive airway pressure (CPAP), the current standard of care ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... , **FDAnews Webinar**, July 16, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... application of human factors engineering to the design of new products as well ...
(Date:6/29/2015)... York, NY (PRWEB) , ... June 29, 2015 ... ... Mount Sinai have developed a new approach to build nearly complete genomes by ... complex forms of genomic variation, critically important for their association with human disease, ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Organization Provides Support for Patients and Families 2Health News:Mesothelioma Organization Provides Support for Patients and Families 3Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 4Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4
... , , , , , ... AUDIO: Scientists at Washington University School of Medicine in St. Louis have found a ... Click here for more information. , , , ... , , , , , ...
... European Society of Cardiology (ESC) is concerned that interpretations ... Lancet (1), could act to deter ongoing research ... density lipoprotein (HDL) cholesterol. Caution, the ESC experts ... results. In the Lancet study, Paul ...
... of the global AIDS community concluded today with clear ... scale up, yet facing an urgent need for increased ... of ,scientifically sound prevention strategies. Delegates and organizers depart ... the theme of Rights Here, Right Now -- with ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, July ... airborne fungus that can cause life-threatening illness -- is an ... Thursday. While C. gattii infections are rare ... they can be severe and even fatal, researchers at the ...
... THURSDAY, July 22 (HealthDay News) -- In small theater ... learning that acting can be a powerful form of therapy, ... deeply personal accounts of mental health issues. "Theater arts ... piece their lives back together," said David A. Faigin, department ...
... happy hour. He sidles up to the bar and orders a ... drink yourself? According to new findings reported in Psychological Science ... determine the extent to which you are influenced by social drinking ... and seeing other people around you drinking. Drinking alcohol increases ...
Cached Medicine News:Health News:Inhibiting fatty acids in immune cells decreases atherosclerosis risk 2Health News:Inhibiting fatty acids in immune cells decreases atherosclerosis risk 3Health News:Inhibiting fatty acids in immune cells decreases atherosclerosis risk 4Health News:No firm conclusions about HDL cholesterol can be drawn from JUPITER sub-analysis 2Health News:No firm conclusions about HDL cholesterol can be drawn from JUPITER sub-analysis 3Health News:Strong scientific findings presented at AIDS 2010 point to promise ahead and underscore the need to stay the course 2Health News:Strong scientific findings presented at AIDS 2010 point to promise ahead and underscore the need to stay the course 3Health News:Strong scientific findings presented at AIDS 2010 point to promise ahead and underscore the need to stay the course 4Health News:Dangerous Fungus Now Endemic in Pacific Northwest: CDC 2Health News:Dangerous Fungus Now Endemic in Pacific Northwest: CDC 3Health News:Taking to the Stage to Battle Mental Illness 2Health News:Taking to the Stage to Battle Mental Illness 3Health News:Taking to the Stage to Battle Mental Illness 4Health News:Can I buy you a drink? Genetics may determine sensitivity to other people's drinking behavior 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: